Tin tức & Cập nhật

The use of fremanezumab is safe and effective for the prevention of episodic migraine (EM) in children and adolescents as young as 6 years old, according to a study presented at AAN 2025.

Treatment with tolebrutinib results in a clear reduction in disability accumulation in patients with relapsing multiple sclerosis (MS) compared with teriflunomide despite no difference in relapses, according to the findings of the GEMINI 1 and 2 trials presented at AAN 2025.

In the treatment of early Alzheimer’s disease (AD), lecanemab is as safe and efficacious in Asian patients as in the wider Clarity AD population, slowing cognitive decline and reducing amyloid levels in the brain with manageable risks.

Interim data from the ongoing 7-year open-label extension (OLE) of the phase IIb X-TOLE study reflect the long-term efficacy and safety of azetukalner, an investigational, potent Kv7 potassium channel opener, for the treatment of adults with focal epilepsy.